Eagle Pharmaceuticals’ (EGRX) Line of Credit Reduced Amid Pending Restatement and Securities Fraud Class Action - Hagens Berman
January 22, 2024 16:03 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Class...
Eagle Pharmaceuticals (EGRX) Shares Crash After CEO Tarriff Resigns and Disclosing Non-Compliance with Nasdaq – Hagens Berman
December 11, 2023 14:30 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Visit:...
Eagle Pharmaceuticals (EGRX) Shares Crash After CEO Tarriff Resigns and Disclosing Non-Compliance with Nasdaq - Hagens Berman
December 04, 2023 15:19 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Visit:...
Eagle Pharmaceuticals (EGRX) Shares Crash After CEO Tarriff Resigns and Disclosing Non-Compliance with Nasdaq - Hagens Berman
December 01, 2023 15:06 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now. Visit:...